Interim results from the SPARK phase II trial report clinical activity for the combination of sitravatinib, a spectrum kinase inhibitor, with tislelizumab, an anti‑PD‑1 antibody, in patients with locally recurrent or metastatic triple‑negative breast cancer (TNBC). The multi‑cohort, single‑arm study evaluated response rates and tolerability across cohorts. Investigators highlighted confirmed responses in a subset of heavily pretreated patients, supporting further exploration of immune‑modulatory kinase inhibition paired with checkpoint blockade in TNBC. Follow‑on studies will need to define predictive biomarkers and survival benefit in randomized settings.